한빛사논문
- 조회2,007
Jung-Ah Kang1,4, Songwon Kim1,4, Minji Park2, Hyun-Jin Park1, Jeong-Hyun Kim1, Sanghyeok Park1, Jeong-Ryul Hwang1, Yong-Chul Kim1, Yoon Jun Kim3, Yuri Cho2,*, Mi Sun Jin1,* & Sung-Gyoo Park1,*
1School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. 2Department of Internal Medicine, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul 06125, Republic of Korea. 3Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. 4These authors contributed equally: Jung-Ah Kang, Songwon Kim
*Correspondence and requests for materials should be addressed to Y.C. or to M.S.J.or to S.-G.P.
Abstract
Chronic hepatitis B virus (HBV) infection can cause cirrhosis and hepatocellular carcinoma and is therefore a serious public health problem. Infected patients are currently treated with nucleoside/nucleotide analogs and interferon α, but this approach is not curative. Here, we screen 978 FDA-approved compounds for their ability to inhibit HBV replication in HBV-expressing HepG2.2.15 cells. We find that ciclopirox, a synthetic antifungal agent, strongly inhibits HBV replication in cells and in mice by blocking HBV capsid assembly. The crystal structure of the HBV core protein and ciclopirox complex reveals a unique binding mode at dimer-dimer interfaces. Ciclopirox synergizes with nucleoside/nucleotide analogs to prevent HBV replication in cells and in a humanized liver mouse model. Therefore, orally-administered ciclopirox may provide a novel opportunity to combat chronic HBV infection by blocking HBV capsid assembly.
논문정보
- Research article
- 2019년 05월 (BRIC 등록일 2019-05-22)
- 국내 연구진
- 생명과학 > 면역학
관련 보도자료
- 바이오스펙테이터
- 2019. 05. 17
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
